Navigation Links
Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis

fection with Gram-negative bacteria, particularly pulmonary P. aeruginosa, represents the single greatest cause of morbidity and mortality among CF patients. Currently there is no known cure for CF, and the goal of CF therapy is to control symptoms and prevent further lung damage.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors. For example, the safety and efficacy data from additional clinical studies may not warrant further development of this compound and initiating and completing clinical trials may take longer or cost more than expected. In addition, future discussions with the FDA may impact the amount of data needed and timelines for review, which may differ materially from Gilead's current projections. Further, the FDA may not approve aztreonam lysine for inhalation for the treatment of CF in the United States, and any marketing approval, if granted, may have significant limitations on its use. If and when regulatory approval is obtained, we will rely on PARI to distribute the device through specialty pharmacies or other distribution channels. If sufficient quantities of this device are not available at the time of a commercial launch or following such a launch, the commercial launch of aztreonam lysine for inhalation could be delayed, and the anticipated contribut
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:8/21/2014)...  Zacks.com announces the list of stocks featured in the ... the latest news and events impacting stocks and the financial ... HPQ - Free Report ), IBM (NYSE: IBM ... - Free Report ), GlaxoSmithKline plc (NYSE: GSK - ... - Free Report ). Today, Zacks is promoting ...
(Date:8/21/2014)...  ACI Clinical ( www.aciclinical.com ) announces a ... Using this solution, trial sponsors can ... costs and receive the same expertise that has ... Leveraging a decade of DMC experience ... statistical programming and meeting facilitation), ACI analyzed DMC ...
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS International, ... Manufacturing Intelligence , today announces Infusion Chicago, ... event will be held Oct. 9-10, 2014, at ... designed to showcase the necessity for implementing a ... and Manufacturing Intelligence to gain insight into production ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2
... SYDNEY, May 23, 2012 HeartWare International, Inc. (NASDAQ: ... of less invasive, miniaturized circulatory support technologies revolutionizing the ... has received an expanded European label for long-term use ... at risk of death from refractory, end-stage heart failure. ...
... ATLANTA, May 23, 2012   CryoLife, Inc. (NYSE: ... focused on cardiac and vascular surgery, announced today that ... Company, LLC One-on-One Investor Conference on Thursday, May 31, ... vice president, chief operating officer, and chief financial officer ...
Cached Medicine Technology:HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure 2HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure 3CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference 2
(Date:8/21/2014)... August 21, 2014 Living in a ... atmosphere that comes along with it. A quality Home ... that such amenities are available. , ... Fayetteville, Georgia and Community Association Management, LLC made a ... Parks Company to provide an additional amenity for their ...
(Date:8/21/2014)... the coronary arteries of chronic kidney disease patients may ... to a new study in the Journal of ... Researchers at the Johns Hopkins Bloomberg School of Public ... used measures of subclinical atherosclerosis in predicting the risk ... Approximately 50 percent of all patients with chronic kidney ...
(Date:8/21/2014)... 2014 Improv performers from Fun House ... dementia at Silverado Turtle Creek memory care community in ... entertainers ranging from ages 10 to 16, delivers a ... 40-minute set. The troupe's philosophy is that improv is ... them to touch audiences regardless of their circumstance — ...
(Date:8/21/2014)... 2014 The City of Garden Grove ... and programming for its inaugural “Re:Imagine Garden Grove – ... 2014, from 11 a.m. to 4 p.m., 2.85-miles of ... and the downtown will be filled with diverse music, ... Arts Resources (CARS), for all to enjoy. , The ...
(Date:8/21/2014)... seniors, dimming vision may be tied to poorer survival, new ... aged 65 to 84, who were assessed when they enrolled ... later. Vision loss over time was associated with an ... period, the researchers reported. Although the study couldn,t prove ... University in West Lafayette, Ind., offered up some theories on ...
Breaking Medicine News(10 mins):Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 2Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 3Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2
... medical practice of Acupuncture along with commonly used ... side effects of chemotherapy for breast cancer patients, ... are to be believed. , , ,According to ... electro-acupuncture was more effective in controlling vomiting than ...
... In what can be a watershed in cancer research, ... have used nuclear transfer technology to harvest life saving ... The same team had earlier cornered world wide fame ... Dolly – the world’s first cloned mammal: Using the ...
... In India Kidney Stones are not uncommon problem due to the ... up of Calcium, Oxalate and phosphates. The cause of stone disease ... water is a risk factor for stone disease. , ... is a tiny bacteria called Nano bacteria., ,These bacteria ...
... be responsible for a form of the herpes virus that ... sarcoma causes purple skin blotches and can also attack the ... normal disease defenses but attacks those with weakened immune system ... virus 8 was discovered six years ago. Almost 30% to ...
... cancer can effect men over the age of 40 years ... cancer. Usually it goes undetected till it is advanced and ... about this condition and now men over the age of ... ,One of the most promising "tumour markers" in medicine ...
... hormone replacement prescription drug, levothyroxine sodium (Unithroid) for hypothyroidism in ... the United States by the FDA. , ,The ... range of metabolic processes within the body in all age ... growth and intellectual development. , ,Low levels of thyroid ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: